{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:25:03Z","timestamp":1771043103626,"version":"3.50.1"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Genetic polymorphisms are related to the concentration and efficacy of oxcarbazepine (OXC). 10-Hydroxycarbazepine (MHD) is the major pharmacologically active metabolite of OXC, and it exerts an antiepileptic effect. This study aimed to explore the connection between the MHD concentration and genes such as ATP-binding cassette B1 (ABCB1), ATP-binding cassette C2 (ABCC2), UDP-glucuronosyltransferase-2B7 and sodium voltage-gated channel alpha subunit 2 (SCN2A), which participate in the antiepileptic function of OXC.<\/jats:p>\n            <jats:p>Total 218 Chinese epileptic patients, were stratified into different groups according to their age, body mass index (BMI) and OXC efficacy. The genotypes of 7 single nucleotide polymorphisms in all subjects were determined by polymerase chain reaction-improved multiple ligase detection reaction assay. The MHD plasma concentration was detected by high-performance liquid chromatography and then standardized through dosage and body weight.<\/jats:p>\n            <jats:p>In general, the ABCC2 rs2273697 mutant (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.026) required a significantly higher standardized MHD concentration. For age groups, carriers of the ABCC2 rs2273697 mutant showed a significantly higher standardized MHD concentration than noncarriers in the juvenile group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.033). In terms of BMI, a significantly higher standardized MHD concentration was found in the ABCB1 rs2032582 mutant of the normal weight group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.026). The SCN2A rs17183814 mutant required a significantly higher OXC maintenance (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.014) in the low-weight group, while lower OXC maintenance dose (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.044) and higher standardized MHD concentration (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.007) in the overweight group.<\/jats:p>\n            <jats:p>The ABCC2 rs2273697 polymorphism was significantly associated with MHD plasma concentration in the whole patient cohort and in patients stratified by different ages, this finding provides potential theoretical guidance for the rational and safe clinical use of OXC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014908","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T11:50:14Z","timestamp":1553169014000},"page":"e14908","source":"Crossref","is-referenced-by-count":26,"title":["Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI"],"prefix":"10.1097","volume":"98","author":[{"given":"Xue","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanliang","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangshuang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongying","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhicheng","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Xiangya Hospital, Central South University, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"R2-20230914","first-page":"4","article-title":"Handbook of epilepsy treatment","volume":"15","author":"Shorvon","year":"2011","journal-title":"Prog in Neur Psych"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1592\/phco.21.11.904.34513","article-title":"Oxcarbazepine in the treatment of epilepsy","volume":"21","author":"Glauser","year":"2012","journal-title":"Pharmacotherapy"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007691-200502000-00004","article-title":"Cost-effectiveness of therapeutic drug monitoring: a systematic review","volume":"27","author":"Touw","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.epilep.2013.01.001","article-title":"Pharmacoresistant epilepsy: definition and explanation","volume":"1","author":"Alexopoulos","year":"2013","journal-title":"Epileptology"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1528-1167.2005.00356.x","article-title":"Genetics of drug resistance","volume":"46","author":"Sisodiya","year":"2010","journal-title":"Epilepsia"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.seizure.2017.07.015","article-title":"Effects of ABCB1, ABCC2, UGT2B7 and HNF4\u03b1 genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy","volume":"51","author":"Shen","year":"2017","journal-title":"Seizure"},{"key":"R8-20230914","first-page":"16","article-title":"ABCB1, ABCC2, SCN1A, SCN2A, GABRA1 gene polymorphisms and drug resistant epilepsy in the Chinese Han population","volume":"70","author":"Zhou","year":"2015","journal-title":"Die Pharmazie"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1755-5949.2012.00336.x","article-title":"ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients","volume":"18","author":"Jian","year":"2012","journal-title":"Cns Neurosci Ther"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.yebeh.2014.05.007","article-title":"Association between MDR1 C3435T polymorphism and refractory epilepsy in the Chinese population: a systematic review and meta-analysis","volume":"36","author":"Cheng","year":"2014","journal-title":"Epilepsy Behav"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1089\/gtmb.2011.0225","article-title":"Role of MDR1 C3435T and GABRG2 C588T gene polymorphisms in seizure occurrence and MDR1 effect on anti-epileptic drug (phenytoin) absorption","volume":"16","author":"Ponnala","year":"2012","journal-title":"Genet Test Mol Biomarkers"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/pgs.14.186","article-title":"SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy","volume":"16","author":"Ma","year":"2015","journal-title":"Pharmacogenomics"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00228-016-2157-3","article-title":"Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy","volume":"73","author":"Lu","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/FPC.0b013e3283528217","article-title":"Genetic association analysis of transporters identifies ABCC2 loci for seizure control in women with epilepsy on first-line antiepileptic drugs","volume":"22","author":"Grover","year":"2012","journal-title":"Pharmacogenet Genom"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jpba.2017.11.041","article-title":"Analysis of unbound plasma concentration of oxcarbazepine and the 10-hydroxycarbazepine enantiomers by liquid chromatography with tandem mass spectrometry in healthy volunteers","volume":"149","author":"Antunes","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2165\/0003088-200847120-00002","article-title":"Does oxcarbazepine warrant therapeutic drug monitoring?","volume":"47","author":"Bring","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/jhg.2017.91","article-title":"The pharmacogenomics of valproic acid","volume":"62","author":"Zhu","year":"2017","journal-title":"J Hum Genet"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.seizure.2015.07.018","article-title":"Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy","volume":"31","author":"Sattler","year":"2015","journal-title":"Seizure"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.seizure.2009.12.004","article-title":"Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy","volume":"19","author":"S\u00e1nchez","year":"2010","journal-title":"Seizure"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1111\/bcp.13392","article-title":"Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children","volume":"83","author":"Rodrigues","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.biochi.2010.04.008","article-title":"Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients","volume":"92","author":"Grover","year":"2010","journal-title":"Biochimie"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"e11662","DOI":"10.1097\/MD.0000000000011662","article-title":"Effects of CYP3A5 and UGT2B7variants on steady-state carbamazepine concentrations in Chinese epileptic patients","volume":"97","author":"Lu","year":"2018","journal-title":"Medicine"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs.12.180","article-title":"Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy","volume":"14","author":"Puranik","year":"2013","journal-title":"Pharmacogenomics"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1365-2125.2009.03437.x","article-title":"Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population","volume":"68","author":"Lakhan","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/FTD.0000000000000538","article-title":"Influence of dose and antiepileptic comedication on lacosamide serum concentrations in patients with epilepsy of different ages","volume":"40","author":"May","year":"2018","journal-title":"Ther Drug Monit"},{"key":"R27-20230914","first-page":"685","article-title":"Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults: study on optimal cut-off points of body mass index and waist circumference in Chinese adults","volume":"11","author":"Zhou","year":"2015","journal-title":"Biomed Environ Sci"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1017\/S0007114514002657","article-title":"Optimal cut-off values of BMI, waist circumference and waist:height ratio for defining obesity in Chinese adults","volume":"112","author":"Qiang","year":"2014","journal-title":"Brit J Nutr"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.dmpk.2015.05.002","article-title":"Polymorphisms of ABCG2, ABCB1 and HNF4a are associated with Lamotrigine trough concentrations in epilepsy patients","volume":"30","author":"Zhou","year":"2015","journal-title":"Drug Metab Pharmacok"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jocn.2016.10.014","article-title":"The ABCC2 c.-24C\u200a>\u200aT polymorphism increases the risk of resistance to antiepileptic drugs: a meta-analysis","volume":"37","author":"Qian","year":"2017","journal-title":"J Clin Neurosci"},{"key":"R31-20230914","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eplepsyres.2016.09.004","article-title":"Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy","volume":"127","author":"Shen","year":"2016","journal-title":"Epilepsy Res"},{"key":"R33-20230914","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/pharmaceutics10030093","article-title":"New ABCC2 rs3740066 and rs2273697 polymorphisms identified in a healthy Colombian Cohort","volume":"10","author":"Bustos-Cruz","year":"2018","journal-title":"Pharmaceutics"},{"key":"R34-20230914","first-page":"47","article-title":"New developments in antiepileptic drug resistance: an integrative view","volume":"9","author":"Dieter","year":"2010","journal-title":"Epilepsy Curr"},{"key":"R35-20230914","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2217\/pgs.13.239","article-title":"ABCC2 rs2273697 and rs3740066 polymorphisms and resistance to antiepileptic drugs in Asia Pacific epilepsy cohorts","volume":"15","author":"Sha\u2019Ari","year":"2014","journal-title":"Pharmacogenomics"},{"key":"R36-20230914","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.09.001","article-title":"Effects of CYP3A4\/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy","volume":"117","author":"Wang","year":"2015","journal-title":"Epilepsy Res"},{"key":"R37-20230914","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4103\/0971-6866.80357","article-title":"Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population","volume":"17","author":"Ritu","year":"2011","journal-title":"Indian J Hum Genet"},{"key":"R38-20230914","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2217\/pgs.13.104","article-title":"SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis","volume":"14","author":"Haerian","year":"2013","journal-title":"Pharmacogenomics"},{"key":"R39-20230914","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/QAD.0000000000000033","article-title":"Common clinical conditions \u2013 age, low BMI, ritonavir use, mild renal impairment affect tenofovir pharmacokinetics in a large cohort of HIV-infected women","volume":"28","author":"Baxi","year":"2014","journal-title":"AIDS"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201903220-00033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:20:39Z","timestamp":1694719239000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201903220-00033"}},"subtitle":["Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms"],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014908","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}